文献速递消化系统肿瘤支持与姑息治疗

血液或骨髓移植后消化道恶性肿瘤

Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant.
PubMed 文献 · JAMA Oncol · 2023-01-01

该队列研究纳入6710例血液或骨髓移植后存活至少2年的患者,随访62479人年,148例发生消化道后续恶性肿瘤。消化道各部位肿瘤标准化发病比范围为结直肠癌2.1至食管癌7.8,阿糖胞苷、依托泊苷、蒽环类药物暴露及慢性移植物抗宿主病与特定消化道肿瘤风险升高相关。

要点

  • 移植后消化道后续恶性肿瘤标准化发病比范围为结直肠癌2.1至食管癌7.8。
  • 清髓预处理使用阿糖胞苷与后续结直肠癌风险升高相关(SHR 3.1)。
  • 合并慢性移植物抗宿主病的异基因移植受者食管癌风险升高(SHR 9.9)。

核心结论

  • 移植后存活者消化道后续恶性肿瘤风险高于一般人群,识别高危亚组可能影响可改变危险因素的建议及个体化筛查。

研究设计与样本

  • 队列研究纳入6710例1974年1月1日至2014年12月31日在希望之城、明尼苏达大学或阿拉巴马大学伯明翰分校接受血液或骨髓移植且存活至少2年的患者,随访截止2020年3月23日。
  • 数据分析于2022年9月1日至2022年9月30日进行。
  • 暴露因素为人口学与临床因素及移植前或移植相关治疗暴露,主要结局为移植后消化道后续恶性肿瘤。

主要发现

  • 队列包括自体移植3444例(51.3%)和异基因移植3266例(48.7%),男性3917例(58.4%),移植时中位年龄46岁(范围0-78岁)。
  • 随访62479人年后,148例发生消化道后续恶性肿瘤。
  • 各部位肿瘤标准化发病比范围从结直肠癌2.1(95%CI 1.6-2.8;P<.001)至食管癌7.8(95%CI 5.0-11.6;P<.001)。
  • 预处理使用阿糖胞苷与后续结直肠癌风险升高相关(SHR 3.1;95%CI 1.5-6.6)。
  • 合并慢性移植物抗宿主病的异基因移植受者较自体移植受者食管癌风险升高(SHR 9.9;95%CI 3.2-30.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Survivors of blood or marrow transplant (BMT) are at increased risk of subsequent malignant neoplasms (SMNs). Cancers of the gastrointestinal (GI) system are of special interest because their clinical behavior is often aggressive, necessitating early detection by increasing awareness of high-risk populations. OBJECTIVE: To describe the risk of SMNs in the GI tract after BMT. DESIGN, SETTING, AND PARTICIPANTS: A cohort study of 6710 individuals who lived at least 2 years after BMT performed between January 1, 1974, and December 31, 2014, at City of Hope, University of Minnesota, or University of Alabama at Birmingham. End of follow-up was March 23, 2020. Data analysis was performed between September 1, 2022, and September 30, 2022. EXPOSURES: Demographic and clinical factors; therapeutic exposures before or as part of BMT. MAIN OUTCOMES AND MEASURES: Development of SMNs in the GI tract after BMT. Participants self-reported SMNs in the GI tract; these were confirmed with pathology reports, medical records, or both. For deceased patients, death records were used. Standardized incidence ratios determined excess risk of SMNs in the GI tract compared with that of the general population. Fine-Gray proportional subdistribution hazard models assessed the association between risk factors and SMNs in the GI tract. RESULTS: The cohort of 6710 individuals included 3444 (51.3%) autologous and 3266 (48.7%) allogeneic BMT recipients. A total of 3917 individuals (58.4%) were male, and the median age at BMT was 46 years (range, 0-78 years). After 62 479 person-years of follow-up, 148 patients developed SMNs in the GI tract. The standardized incidence ratios for developing specific SMNs ranged from 2.1 for colorectal cancer (95% CI, 1.6-2.8; P < .001) to 7.8 for esophageal cancer (95% CI, 5.0-11.6; P < .001). Exposure to cytarabine for conditioning (subdistribution hazard ratio [SHR], 3.1; 95% CI, 1.5-6.6) was associated with subsequent colorectal cancer. Compared with autologous BMT recipients, allogeneic BMT recipients with chronic graft-vs-host disease were at increased risk for esophageal cancer (SHR, 9.9; 95% CI, 3.2-30.5). Conditioning with etoposide (SHR, 2.0; 95% CI, 1.1-3.5) and pre-BMT anthracycline exposure (SHR, 5.4; 95% CI, 1.3-23.4) were associated with an increased risk of liver cancer compared with no exposure to the respective agents. CONCLUSIONS AND RELEVANCE: The findings of this cohort study are relevant for oncologists and nononcologists who care for the growing number of survivors of transplant. Awareness of subgroups of survivors of BMT at high risk for specific types of SMNs in the GI tract may influence recommendations regarding modifiable risk factors, as well as individualized screening.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. McDonald A, Dai C, Meng Q, et al. Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant. JAMA Oncol. 2023. PMID: 36656600. doi:10.1001/jamaoncol.2022.6569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。